Profil at EASD Annual Meeting 2018

Meet the people behind Profil 

About EASD Annual Meeting

Profil will be present at EASD Annual Meeting with numerous posters as well as some presentations. Of course we look forward to this exciting event very much. 

We are proud that Profil will be a sponsor of Solvable Problems in Diabetes at EASD Annual Meeting 2018 in Berlin. The event will take place on Thursday, October 4, 2018, from 7:00-9:00 pm during the 2018 annual meeting for the European Association of the Study of Diabetes (EASD). Learn more about the event here. 

Win a ticket to the event "Solvable Problems in Diabetes" 

Profil is giving away 2 tickets to the event "Solvable Problems in Diabetes" at EASD Annual Meeting 2018 in Berlin, Germany on October 4, 2018. 

To participate in the raffle, please write an e-mail with the subject "Raffle EASD Annual Meeting 2018" and your contact data to svenya.meister@profil.com before September 25, 2018. All e-mails that we received with the correct subject until September 25, 2018 will participate in the raffle. Each of the three winners will get one ticket for "Solvable Problems in Diabetes" at EASD Annual Meeting 2018 in Berlin, Germany on October 4, 2018.

Please read the rules of participation.

Our scientific contributions at the EASD Sessions 

Oral Presentations

• 60 - Ultra rapid lispro (URLi) reduces postprandial glucose excursions vs lispro in patients with type 1 diabetes at multiple meal-to-dose timing intervals
• 150 - Nasal glucagon: a viable alternative to treat insulin-induced hypoglycaemia in adults with type 1 diabetes
• 164 - MEDI0382, a dual GLP-1 glucagon receptor agonist, promotes rapid glucose control and significant weight loss in patients with type 2 diabetes
• 57 - The ultra-rapid insulin BioChaperone Lispro shows favourable pharmacodynamics and pharmacokinetics compared to faster insulin aspart and insulin aspart in insulin pumps

Poster Presentations

• 814 - Ultra rapid lispro (URLi) reduces postprandial glucose excursions vs lispro in patients with type 2 diabetes at multiple meal-to-dose timing intervals
• 817 - Ultra rapid lispro (URLi) shows faster insulin absorption vs lispro during insulin pump (CSII) use in patients with type 1 diabetes
• 718 - MEDI0382, a glucagon-like peptide/glucagon receptor dual agonist, in patients with type 2 diabetes: a multiple-ascending-dose study
• 743 - Robust glucose control and weight loss after 6 weeks of treatment with MEDI0382, a balanced GLP-1/Glucagon receptor dual agonist, in patients with type 2 diabetes
• 818 - Better postprandial glucose control with BioChaperone Combo than with lispro Mix25 or separate glargine and lispro (G+L) administrations in subjects with type 2 diabetes
• 816 - BioChaperone 222, the new excipient enabling the ultra-rapid BioChaperone Lispro formulation, is completely absorbed and rapidly excreted after subcutaneous injection
• 815 - Pooled analysis of clinical trials investigating the pharmacokinetics (PK) of ultra-rapid insulin BioChaperone Lispro vs lispro in subjects with type 1 and type 2 diabetes

Other things you should know about the EASD Annual Meeting

• You can meet with a Profil representative at the occasion of the EASD Annual Meeting to discuss your research or product developments. Just send an email to lars.bochmann@profil.com or fill out the form on the right.